Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Southern Cross Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (263)
Cancellation by sponsor (201)
Prescription medicine registration (22)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (16)
2023 (30)
2022 (102)
2021 (32)
2020 (52)
2019 (59)
2018 (35)
2017 (51)
2016 (22)
2015 (17)
2014 (9)
2013 (11)
2012 (19)
2011 (9)
2010 (10)
2009 (13)
2008 (3)
2007 (1)
2003 (1)

Results for "[search-keyword]"

Search

Sponsor content

492 result(s) found, displaying 151 to 160

CEFAZOLIN RMB cefazolin (as sodium) 1000 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
CEFAZOLIN AJS cefazolin (as sodium) 1000 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE TLB moxonidine 200 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE AJS moxonidine 200 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE AJS moxonidine 400 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE RMB moxonidine 200 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE RMB moxonidine 400 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MOXONIDINE TLB moxonidine 400 microgram film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
ANAGRELIDE MGH anagrelide (as hydrochloride monohydrate) 0.5 mg capsule bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
TEICOPLANIN MGH teicoplanin 400 mg powder for injection with diluent ampoule Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd

Pages

First page
Previous page
…
Page 12
Page 13
Page 14
Page 15
Current page 16
Page 17
Page 18
Page 19
Page 20
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.